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Exposure to microbe-associated molecular patterns (MAMPs)
causes dendritic cells (DCs) to undergo a remarkable activation
process characterized by changes in key biochemical mechanisms.
These enhance antigen processing and presentation, as well as
strengthen DC capacity to stimulate naïve T cell proliferation.
Here, we show that in response to the MAMPS lipopolysaccharide
and polyriboinosinic:polyribocytidylic acid (Poly I:C), RNA polymer-
ase III (Pol lII)-dependent transcription and consequently tRNA
gene expression are strongly induced in DCs. This is in part caused
by the phosphorylation and nuclear export of MAF1 homolog neg-
ative regulator of Poll III (MAF1), via a synergistic casein kinase 2
(CK2)- and mammalian target of rapamycin-dependent signaling
cascade downstream of Toll-like receptors (TLRs). De novo tRNA
expression is necessary to augment protein synthesis and compen-
sate for tRNA degradation driven by TLR-dependent DC exposure
to type-I IFN. Although protein synthesis is not strongly inhibited
in absence of RNA Pol III activity, it compromises the translation
of key DC mRNAs, like those coding for costimulatory molecules
and proinflammatory cytokines, which instead can be stored in
stress granules, as shown for CD86 mRNA. TLR-dependent CK2
stimulation and subsequent RNA Pol III activation are therefore
key for the acquisition by DCs of their unique T cell immune-
stimulatory functions.
casein kinase 2 | interferon | protein synthesis | CD86 | immunity
Dendritic cells (DCs) are key regulators of both protectiveimmune responses and tolerance to self-antigens (1). DCs
are professional antigen presenting cells (APCs), equipped with
pattern recognition receptors, like Toll-like receptors (TLRs),
capable of recognizing and responding to microbe-associated
molecular patterns (MAMPs) (2). For example, lipopolysaccha-
ride (LPS) detection by TLR4 promotes DC activation by trig-
gering a series of signaling cascades resulting in massive changes in
gene expression, membrane traffic, and metabolism. This matu-
ration process ultimately culminates in the priming of naïve T cell
recognizing antigenic peptides presented by major histocompati-
bility complexes (MHCs) and costimulatory molecules at the
surface of activated DCs (3, 4). LPS-stimulated DCs undergo a
phase of rapid up-regulation of protein synthesis mediated in part
through the mammalian target of rapamycin (mTORC1) signal
transduction pathway. This up-regulation is necessary for cytokine
production and rapid increase in surface MHC class II and
costimulatory molecules, like B7.1/CD86 (5). Importantly the se-
cretion of type-I IFN (IFN) contributes majorly to the speed and
intensity of DCmaturation in an autocrine manner (6). The role of
RNA polymerase III (Pol III) activity and tRNA gene expression
during DC activation has remained unexplored. Pol III is re-
sponsible for the transcription of some 300 different genes (class
III genes), that are mostly tRNAs (7). In-depth analysis of Pol III
activity has revealed a cascade of coordinated interactions of
transcription factors to recruit Pol III and allow the transcription
of tRNA genes. TFIIIC binding to intragenic conserved promoters
is followed by assembly of initiation factor TFIIIB subunits (Brf1,
Bdp1, and TBP) and binding to upstream sequences, that lead to
the subsequent recruitment of the Pol III subunits (8–10). Pol III is
normally controlled by the general negative regulator MAF1 (11),
which binds to the polymerase and impairs its recruitment to the
promoter DNA/TFIIB complex, and thus prevents transcription
initiation.
We show here that TLR agonists drive up global tRNA
transcription during the first hours of DC activation. Following
LPS stimulation, enhanced Pol III transcription is achieved
through the concerted actions of casein kinase 2 (CK2) and
mTORC1 on the MAF1 repressor. TLR-dependent nuclear
translocation of both CK2 and mTORC1 causes MAF1 phos-
phorylation and cytosolic accumulation over time, consequently
allowing for Pol III transcriptional activation. This cascade of
signaling events enhancing tRNAs expression is necessary to in-
crease protein synthesis and harness DCs with the full immune-
stimulatory potential required for priming naïve T cells. We also
found that DC exposure to type-I IFN accelerates tRNA turnover.
Enhanced Pol III transcription upon TLR triggering is therefore
necessary to compensate for IFN-dependent tRNA decay, which
would, in absence of this mechanism, drive the formation of stress
granules (SGs) and prevent the translation of key mRNAs, such as
CD86, in activated DCs. These SGs differ from the SGs formed by
environmental stress, since they are independent of full protein
synthesis inhibition and increased eukaryotic translation initiation
factor 2 alpha subunit (eIF2α) phosphorylation, 2 hallmarks of
SGs formed in response to oxidative stress (12). The CK2/MAF1/
Pol III axis represents therefore a previously unidentified signaling
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cascade downstream of TLRs, that is essential for naïve T cell
priming by DCs.
Materials and Methods
Cell Culture. Bone marrow (BM)-derived DCs were differentiated in vitro from
6- to 8-wk-old femalemice bonemarrowwith granulocytemacrophage colony-
stimulating factor (GM-CSF) (13). Mouse splenocytes were obtained by disso-
ciation of spleens using Liberase TL, followed by a 25-min incubation at 37 °C.
Cells were washed (1× PBS + 2% FBS [FCS] + 2mM EDTA) and passed in a 70-mm
cell strainer and centrifuged for 5 min at 4 °C. DCs were purified using
CD11c Positive Selection Kit from Milteny (CD11c MicroBeads UltraPure)
according to manufacturer’s instructions for prior culture in RPMI and 10% FCS.
All experiments were approved by the Comité d’Éthique de Marseille and the
Direction Départementale des Services Vétérinaires des Bouches du Rhône
(approval no. A13-543).
Flow Cytometry. Cell were harvested and washed with PBS, incubated with
the antibodymixture diluted in cold fluorescence-activated cell sorting (FACS)
buffer for 30 min at 4 °C. Intracellular staining was performed after fixation
with Cytofix/Cytoperm (BD Biosciences), by incubation with antibody mix-
ture diluted in PermWash (BD Biosciences). Samples were acquired on a FACS
Canto II and analyzed with FlowJo (Tree Star). Antibodies used were CD11c
(N418) and CD86 (GL-1) from BioLegend and MHCII (M5/114.15.2) from
eBioscience. For the spleen cells, the antibodies were CD11c (N418), CD8α
(53-6.7), and MHCII (M5/114.15.2) from eBioscience; BST2 (927), CD86 (GL-1),
and SiglecH (551) from BioLegend; and CD11b (M1/70) and B220 (RA3-6B2)
from BD Biosciences.
Immunoblotting. Cell pellets were extracted with radioimmunoprecipitation
assay (RIPA) buffer supplemented with complete protease and phosphatase
inhibitor mixture tablets (Roche). Protein quantification was done with the
bicinchoninic acid (BCA) protein assay (Pierce). A total of 20 to 25 μg of sample
was run in SDS–polyacrylamide gels and Phos-Tag polyacrylamide gels. Anti-
bodies against eIF2α, p-eEF2(Thr56), eEF2, p-AKT, AKT, and p-p65 were from
Cell Signaling. Antibody against p-eIF2α(S51) was from ABCAM; antibody
against β‐actin was from Sigma. Mouse antibody against puromycin (25D1) was
purchased fromMerck Millipore. Antibody against p-eIF2β was a kind gift from
David Litchfield, University of Western Ontario, London, ON, Canada. Antibody
against eIF2β and p-65 was purchased from Santa Cruz Biotechnology. HRP
secondary antibodies were from Jackson ImmunoResearch Laboratories.
Northern Blot. Northern blots were performed as previously described (14). In
short, total RNA was extracted using TRIzol (Invitrogen) and resolved on
15% polyacrylamide gels and transferred to a nitrocellulose membrane
(Hybond N, Amersham) that was crosslinked using a UV Stratalinker 1800
(Stratagene). Membranes were hybridized overnight at the melting tem-
perature (Tm) of the nucleotides lowered by 5 °C, then scanned and ana-
lyzed using ImageJ.
ELISA. Mouse IL-6 and TNF-α were quantified using an appropriate ELISA kit
(eBioscience) according to the manufacturer’s instructions.
Further detailed methods are provided in SI Appendix.
Results
tRNAs Are Up-Regulated during DC Activation by MAMPs. We used
microarrays capturing all tRNA isoacceptors (15, 16) to monitor
globally their expression in LPS-activated bone marrow-derived
DCs (bmDCs). tRNA levels were quantified after 4 h and 8 h of
LPS activation in WT and IFN receptor-deficient (IFNAR−/−)
bmDCs (Fig. 1A and SI Appendix, Tables S2 and S3). IFNAR−/−
cells display a delayed response to LPS, caused by their incapacity
to sense autocrine type-I IFN, a key potentiator of their activation
(6). LPS stimulation up-regulated most tRNA isoacceptors after 4 h,
followed by a return to preactivation levels after 8 h (Fig. 1A). In
IFNAR−/− DCs, tRNA expression remained nearly unchanged in
the first hours of LPS activation, whereas up-regulation was ob-
served after 8 h of stimulation. The expression of several tRNAs
(e.g., Arg-CCU, Lys-UUU1, Gln-C/UUU, Ala-A/C/UGC, Ile-
IAU, Leu-A/UAG, Leu-CAG, and Leu-UAA2) was even aug-
mented compared to the levels found in 4-h LPS-stimulated
WT cells (SI Appendix, Tables S2 and S3). These variations
likely reflect the key contribution of type-I IFN to DC maturation
(SI Appendix, Fig. S1) (6), but also suggest that DC activation by
type-I IFN could impact the stability or turnover of tRNAs.
To extend our analysis to physiologically relevant DC types
and stimuli, we performed qPCR and Northern blot to monitor
tRNATyr (GUA), tRNAThr (AGU), and tRNAArg (UCU) expression
in activated bmDCs (Fig. 1 B and C) or CD11C+ splenic DCs
(Fig. 1D). The TLR3 agonist Poly I:C was chosen next to
TLR4-dependent stimulation with LPS, because Poly I:C pro-
motes mostly type-I IFN production in DCs and drives a slower
kinetics of activation (13). tRNA expression was found to be
augmented by 2- to 3-fold after 8 h of stimulation with Poly I:C.
Activated IFNAR−/− bmDCs displayed little induction of these
tRNAs compared to their WT counterparts (Fig. 1B). The latter
result was confirmed by Northern blot for tRNATyr (GUA) ex-
pression, which increased in response to both MAMPs (Fig. 1C),
but not in absence of IFNAR. Increased tRNATyr expression was
also observed in primary splenic DCs (Fig. 1D), further demonstrat-
ing the general relevance of these observations. Importantly,
tRNATyr was unchanged following treatment with the RNA Pol III
inhibitor ML-60218 (17) (Fig. 1E), suggesting that RNA Pol III
activity and de novo tRNA transcription is involved in DC matu-
ration. Increased tRNATyr expression was paralleled by an up-
regulation of the RNA polymerase III subunit C mRNA
(Polr3C) (Fig. 1F), potentially contributing to the increased tRNA
transcription in activated DCs. Importantly, RNA Pol III has been
described as a sensor for viral DNA (18), and the lack of Polr3C
mRNA induction in activated IFNAR−/− DCs (Fig. 1F) suggests
that Polr3C, like many cytosolic nucleic acid sensors, behaves as an
IFN-stimulated gene (ISG).
To gain a better understanding of tRNA homeostasis with
respect to IFNAR signaling, we investigated the turnover of
tRNATyr (GUA) following treatment with LPS and RNA Pol III
inhibitor by Northern blot (Fig. 1G) and qPCR (Fig. 1H). Al-
though tRNAs are believed to be stable and long lived in most
cells (19), we found that 30 to 50% of tRNATyr (GUA) were
degraded in DCs after 7 h of LPS activation, in absence of active
Pol III transcription. This decay did not occur upon IFNAR de-
letion (Fig. 1 G and H), indicating that type-I IFN detection
compromises tRNA stability and that enhanced Pol III transcrip-
tion is required to maintain sufficient tRNA levels to sustain active
protein synthesis during DC activation.
RNA Pol III Activity Is Required for DC Activation. Pol III inhibition
with ML-60218 did not affect protein synthesis in nonactivated
DCs, but efficiently prevented its augmentation triggered by
LPS or Poly I:C, as monitored by puromycin incorporation
(Fig. 2A). A similar observation was made upon treatment with
2-deoxy-glucose (2-DG) (Fig. 2B), that inhibits the glycolytic
shift required for full DC activation (20, 21) and serves here as
a pharmacological control.
Given the inhibitory activity of ML-60218 on the protein syn-
thesis up-regulation normally driven by LPS stimulation, we ex-
plored the consequences of inhibiting Poll III on the translation
machinery organization in activated DCs. We monitored by con-
focal microscopy the formation of stress granules in different
conditions (Fig. 2C) (12). SGs form in the cytoplasm of cells ex-
posed to acute stress (e.g., oxidative stress) concomitantly with
eIF2α phosphorylation and global inhibition of the protein syn-
thesis. SGs store mRNAs mostly stalled at initiation in complexes
with 40S ribosomal subunits, P-eIF2α and RNA-binding proteins,
e.g., G3BP-stress granule assembly factor 1 (G3BP1). SGs are
located in the vicinity of other RNA–protein organelles, the P
bodies that concentrate the mRNA decay machinery, such as
the decapping mRNA 1A enzyme (DCP1A) and participate in
RNA turnover through constant exchanges with SGs (12, 22).
Enhanced SG formation was observed in control DCs treated with
arsenite (Ars, 30 min), monitored by the G3PB1 SG marker (Fig.
2C). A moderate increase in SG formation was also detected in
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Fig. 1. Alterations of tRNA transcription following DC activation byMAMPs. (A) Heatmap of tRNA expression levels measured by tRNA-tailoredmicroarrays ofWT
and IFNAR−/− DCs stimulated with LPS for 4 and 8 h. Data (n = 2) are relative to the expression levels at time point zero. tRNAs are presented by their cognate
amino acid and anticodon. Meti-CAU and Met-CAU are initiator and elongator tRNAMet (CAU), respectively. (B) tRNATyr (GUA), tRNAThr (AGU), and tRNAArg (UCU)
levels measured by RT-qPCR in WT and IFNAR−/− DCs stimulated with LPS or Poly I:C for 4 and 8 h. (C) tRNATyr (GUA) levels measured by Northern blot in WT and
IFNAR−/− DCs; densitometry quantifications are shown (Right). (D) tRNATyr (GUA) levels measured by RT-qPCR in bmDCs and CD11c+ spleen DCs. (E) tRNATyr (GUA)
levels measured in LPS or Poly I:C-activated DCs, treated with the Pol III inhibitor ML-60218 by RT-qPCR. (F) Polr3c mRNA levels measured by RT-qPCR in WT and
IFNAR−/− DCs. (G) Northern blot analysis of tRNATyr (GUA) decay in LPS-activated WT and IFNAR−/− DCs treated with ML-60218 for indicated time; densitometry
quantification is shown (Right). (H) Decay of tRNATyr (GUA) analyzed by RT-qPCR inWT and IFNAR−/−DCs after 7 h of LPS andML-60218 treatment. Data in B–H are
mean ± SD (n = 3). n.s., nonsignificant results; *P < 0.05, **P < 0.01 by unpaired Student’s t test.
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Fig. 2. Pol III activity contributes to DC activation. (A) Protein synthesis was measured by flow cytometry using puromycin incorporation in LPS- or Poly I:C-
stimulated DCs treated or not with ML-60218 for 8 h or (B) with 2-DG. (C) Immunofluorescence microscopy for G3BP1 and DCP1A in Ars-treated (30 min) or LPS-
activated DCs treated with or without ML-60218. SG and DCP1A foci quantification is shown at the Bottom. Arsenite-treated cells were used as positive control.
G3BP1-positive SGs are indicated by arrowheads. (Scale bar, 10 μm.) Quantification of G3BP1- and DCP1A-positive granules is shown at the Bottom. (D) Levels of
phosphorylated and total eIF2α and eIF2βmonitored by immunoblot. (E) In situ hybridization fluorescence staining for CD86 mRNA, along with SG marker (G3BP1)
in LPS-stimulated DCs treated or not with ML-60218. Arsenite treatment was used as positive reference. CD86 mRNA localized in SG is indicated by arrowheads.
(Scale bar, 10 μm.) All images are representative of n = 3 independent experiments. Data in A–D are mean ± SD (n = 3). (A and B) *P < 0.05, **P < 0.01, ***P <
0.001 by unpaired Student’s t test. Data in C and D are mean ± SD (n = 3), n.s., nonsignificant results; **P < 0.01 and ****P < 0.0001 with multiple comparison with
Holm–Sidak correction.
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LPS-activated DCs. However, treatment with ML-60218 alone or in
combination with LPS caused even higher formation of SGs and P
bodies/DCP1A foci (Fig. 2C). Surprisingly, and unlike SGs assem-
bling upon oxidative stress, ML-60218–dependent foci formed in-
dependently of eIF2α phosphorylation, which like phosphorylated
eIF2β remained unaffected by ML-60218 (Fig. 2D). These gran-
ules were insensitive to the integrated stress response inhibitor
(ISRIB) (Fig. 2D and SI Appendix, Fig. S2), a small inhibitor of the
integrated stress response interfering with SGs (23). This suggests
the existence of an alternative pathway governing SGs upon de-
pletion of tRNAs and other Pol III-dependent transcripts (24),
which facilitates SG formation without heavy eIF2α phosphoryla-
tion and full protein synthesis inhibition, as opposed to what is
observed upon Ars treatment (Fig. 2D) (12). These SGs sequester
mRNAs encoding activated DC transcripts, like the costimulatory
receptor CD86 mRNA, which associated with G3BP1 in both ML-
60218 or Ars treatment (Fig. 2E). mRNA segregation in SGs likely
prevents their translation, inferring that enhanced Pol III tran-
scription by TLR agonists is a crucial function that controls protein
synthesis, both quantitatively and probably qualitatively, during
DC functional activation.
Casein Kinase 2 Controls Pol III Activation. Pol III-mediated tran-
scription is inhibited via a mechanism that depends on the nuclear
accumulation of the MAF1 repressor, followed by its physical as-
sociation with the polymerase (25). In yeast, phosphorylation of
MAF1 by casein kinase II (CK2) is required for efficient Pol III
transcription (26). We monitored MAF1 phosphorylation levels by
Phos-Tag immunoblots and found them to be strongly enhanced
following DC stimulation both with LPS and Poly I:C (Fig. 3A).
Increased P-MAF1 levels were associated with its export out of the
nucleus, as visualized by confocal microscopy in LPS-stimulated
cells (SI Appendix, Fig. S3). We next investigated the consequences
of MAF1 activity on tRNA transcription by silencing its expression
or overexpressing it ectopically. Abrogation of Maf1 expression by
RNAi strongly augmented tRNATyr expression in steady-state DCs
to levels observed in the activated cells (Fig. 3 B, Left). Conversely,
MAF1 overexpression prevented up-regulation of tRNATyr upon
LPS stimulation (Fig. 3 B, Right). Our results suggest that MAF1 is
a key transcription factor controlling tRNA transcription during
DC activation.
The involvement of CK2 in this process was tested using CX-
4945, a specific inhibitor currently used in clinical trials (27, 28).
Immunoblotting for different targets of CK2 (AKT and eIF2β)
was performed to confirm CX-4945’s specificity in DCs (Fig. 3C).
AKT and eIF2β phosphorylation was completely abolished fol-
lowing CX-4945 treatment, demonstrating its efficacy in vitro.
CX-4945 also prevented P-MAF1 accumulation in both steady-
state and activated DCs (Fig. 3D) and inhibited its nuclear export
in response to LPS (SI Appendix, Fig. S3). As anticipated from the
inhibition of Pol III activity by MAF1, TLR-dependent en-
hancement of tRNATyr (GUA) transcription was completely ab-
rogated by CX-4945 (Fig. 3D). This confirms that CK2 activity
controls Pol III through MAF1 phosphorylation upon TLR
stimulation. Treatment with rapamycin, a potent mTOR inhibitor,
had the same effects (SI Appendix, Fig. S4), suggesting that both
CK2 and mTORC1 act together to control Pol III transcription
during DC activation. MAF1 phosphorylation has to be efficient
to fully unleash Pol III transcription. Immunoproximity ligation
assay (iPLA) showed that upon stimulation with LPS, CK2 can be
found in the nucleus, in close vicinity of the BRF1 subunit of
TFIIIB, that recruits Pol III on tRNA promotors together with
MAF1 (Fig. 4A). During activation, MAF1/CK2 (Fig. 4B) or
MAF1/MTOR (SI Appendix, Fig. S4D) complexes were mostly
found in the cytosol (1.5 h), before accumulating in nuclei of
activated cells at later times (3 or 6 h). This confirms that TLR
signaling causes both CK2 and mTORC1 migration into the nu-
cleus to promote MAF1 export and potentiate Pol III activation,
contributing to enhanced protein synthesis and acquisition of their
immune-stimulatory function by DCs. The inhibitory effect of CX-
4945 on tRNA expression and protein synthesis was confirmed by
the formation of SGs in treated control or LPS-activated DCs
(Fig. 4C), further suggesting that CK2 activity is also required in
steady-state DCs to promote Pol III activity and basal tRNA
transcription.
CK2 and Pol III Are Required for T Cell Priming by DCs. DCs treated
with CX-4945 were deficient in their activation, as demonstrated
by the lack of up-regulation of surface CD86 and MHCII in re-
sponse to LPS and Poly I:C (Fig. 5A). We also demonstrate that
CK2 inhibition by CX-4945, in addition to blocking phosphoryla-
tion of AKT and the ribosomal protein S6, also strongly prevented
NF-κB p65 phosphorylation (Fig. 5B) (29). This likely interferes
with DC activation and proinflammatory cytokine production,
providing direct evidence of the capacity of CK2 to control signal
transduction downstream of TLRs. Inhibition of the NF-κB sig-
naling pathway is probably the dominant feature of CX-4945, that
synergizes with the reduction in tRNA expression to prevent DC
activation. To unravel the singular impact of inhibiting Pol III
transcription on DC immunological function, we monitored by
flow cytometry the surface expression of costimulatory molecules
after DC stimulation in presence of ML-60218. Similarly to gly-
colysis inhibition by 2-DG treatment, used as a positive control,
surface CD86 and CD40 expression was strongly reduced by ML-
60218, for both of the TLR agonists used (Fig. 5C), while se-
cretion of IL-6 and TNF-α was also inhibited (Fig. 5D). ML-
60218 clearly affected translation, since expression of cytokine
mRNAs remained untouched by the treatment (Fig. 5D). The
deficit in costimulatory molecule expression caused by RNA Pol
III inhibition was further evaluated following the activation of
primary OT2 T cells with ovalbumin peptide (323 to 339)-loaded
DCs (Ova-DCs). CellTrace Violet was used to follow T cell pro-
liferation after priming with control or ML-60218–treated DCs. As
expected from the reduced expression of both surface CD86 and
CD40, OT2 proliferation was strongly reduced when stimulation
was provided by RNA Pol III-inhibited Ova-DCs, irrespective of
their activation by either LPS or Poly I:C (Fig. 5E). This inability to
prime naïve T cells observed in the ML-60218–treated DCs, was
coincident with a lack of CD4+ T regulatory cell induction, here
visualized by the expression the transcription factor Foxp3 in OT2
T cells after activation with control Ova-DCs (Fig. 5E). Pol III
activity and tRNA gene expression are therefore necessary for
DCs to acquire their unique immune-stimulatory capacity in re-
sponse to TLR agonists.
Discussion
Activated phagocytes or rapidly dividing T cells have important
metabolic demands and show strong requirements for energy
production and macromolecule biosynthesis (21). Translation is a
key step in regulating gene expression and one of the most energy
consuming processes in the cell. It is thus predictable that me-
tabolism and protein synthesis should be coordinated by common
signaling pathways (30). We have shown that LPS stimulation has a
profound impact on the intensity and quality of translation in DCs
both in vitro and in vivo (5). This enhancement in protein synthesis
is controlled downstream of TLR4 by the PI3K/AKT/mTOR signal
transduction pathway and is necessary for cytokine production, as
well as the up-regulation of surface costimulatory molecules and
MHC class II. We report here that casein kinase 2 activity parallels
and potentially synergizes with the AKT/mTOR axis to achieve
protein synthesis up-regulation and full DC activation.
CK2 has been described as a stress-activated protein kinase,
potentially involved in mRNA translation control (31). Several
translation factors are directly phosphorylated by CK2, including
subunits of eukaryotic initiation factors eIF3 and eIF5 (32,
33). This impact on protein synthesis, together with the physical
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Fig. 3. MAF1-dependent Pol III activity is controlled by CK2. (A) MAF1 phosphorylation in DCs stimulated with LPS and Poly I:C was analyzed by Phos-Tag
immunoblotting; β-actin serves as control. Quantification is shown on the Right. (B) Maf1 silencing in DCs (Maf1 KD) and LPS activation for 4 h. Scrambled
siRNA (SC) serves as control. Maf1 overexpression in DCs (PMAF) compared to control transfected with empty vector (PE). tRNATyr (GUA) and Maf1 mRNA
levels were analyzed by RT-qPCR. Data are mean ± SD (n = 3). (C) LPS-activated DCs treated or not with CK2 inhibitor CX-4945 were subjected to immu-
noblotting. Levels of p-AKT, total AKT, p-eEF2, total eEF2, p-eIF2β, total eIF2β, p-eIF2α, and total eIF2α were analyzed. All data (mean ± SD) are representative
of n = 3 independent experiments; quantification is shown on the Right. (D) Phos-Tag immunoblotting for P-MAF1 in DCs stimulated with LPS, Poly I:C, and
treated with CX-4945 for 8 h; β-actin is used as control. Levels of tRNATyr (GUA) were measured by RT-qPCR. Data are mean ± SD (n = 3). In B–D n.s., non-
significant results; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 were obtained by unpaired Student’s t test.
6 of 9 | www.pnas.org/cgi/doi/10.1073/pnas.1904396116 Reverendo et al.
interaction, direct phosphorylation, and cross-regulation of AKT
by CK2, partially explains the correlation between CK2 activity
and elevated rates of cell proliferation (34). Upon TLR stimu-
lation by MAMPs, CK2 plays a key role in coordinating RNA Pol
III-dependent tRNA transcription and raises protein synthesis
activity to the level required to achieve DC maturation. Direct
targeting by CK2 of the nuclear repressor MAF1, in synergy with
mTORC1 activity, is required for these processes, thus con-
firming that in mammalian cells, similar mechanisms exist as
those seen in yeast switching from respiratory conditions to
fermentative growth (26). Basal CK2 activity is necessary to
maintain AKT, MAF1, and NF-κβ phosphorylation in steady-
state DCs, suggesting that CK2 inhibitors could have strong
antiinflammatory properties by targeting several key pathways
for DC homeostasis and activation.
One of the major consequences of CK2-dependent Pol III
activation associated with TLR signaling is the up-regulation of
tRNA expression. We demonstrated that enhanced Pol III ac-
tivity is necessary to maintain ad hoc protein synthesis levels in
LPS-activated DCs, but not in resting cells. Pol III inhibition
Fig. 4. CK2 is a regulator of Pol III activity. (A and B) iPLA of DCs stimulated with LPS for indicated time and stained for BRF1 and CK2a (A), or MAF1 and CK2a
(B). (C) Confocal microscopy for G3BP1 and DCP1A of DCs stimulated with LPS and treated with CX-4945. Cells treated 30 min with arsenite were used as
positive reference. G3BP1-positive SGs are indicated by arrowheads. (Scale bar, 10 μm.) All Images are representative of n = 3 independent experiments.
Quantification (mean ± SD) is shown on the Right. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 were obtained with multiple comparison with
Holm–Sidak correction.
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Fig. 5. Pol III activity is required for DC activation and T cell priming. (A) DCs stimulated with LPS, Poly I:C, and treated with CX-4945. Surface up-regulation of
costimulatory molecules CD86 andMHCII was measured by flow cytometry and is presented as mean fluorescence intensity (MFI). (B) DCs activatedwith LPS, treated
with CK2 inhibitor CX-4945 for 8 h, and processed for immunoblotting. Analysis of p-p65, p65, p-S6, and S6 levels. (C) DCs stimulated with LPS, Poly I:C, and treated
with the Pol III inhibitor ML-60218 for 8 h. Surface up-regulation of costimulatory molecules CD86 and CD40 was measured by flow cytometry and is presented as
MFI. DCs were also stimulated with LPS, Poly I:C, and treated with 2-DG for 8 h, and surface CD86 levels were analyzed by flow cytometry. Data are mean ± SD (n =
3). *P < 0.05, **P < 0.01, ***P < 0.001 by unpaired Student’s t test. (D) The concentrations of secreted IL-6 and TNF-α were measured by ELISA. IL-6 and TNF-αmRNA
levels were quantified by RT-qPCR. Data are mean ± SD (n = 3). ***P < 0.001 by unpaired Student’s t test. (E) OT-II proliferation assay. DCs stimulated with LPS, Poly
I:C, and treated with ML-60218 for 8 h and loaded with the OVA 323 to 339 peptides. DCs were incubated with CellTrace Violet (CVT)-labeled OT-II/Rag-2−/− T cells
for 4 d and analyzed by flow cytometry for CTV dilution and Foxp3 expression. Quantification of the percentage of proliferating OT-II cells and Foxp3+ cells are
shown on the Right. Data are mean ± SD (n = 3). n.s., nonsignificant results; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by unpaired Student’s t test.
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causes accumulation of mRNAs in SGs and prevents the up-
regulation of surface molecules, like CD86 or CD40, necessary
for mature DCs to prime naïve T cells. tRNA synthesis and Pol
III transcription are therefore necessary to achieve functional DC
activation, to the same extent as the glycolytic switch observed
upon TLR stimulation. DC activation by MAMPs is almost sys-
tematically associated with type-I IFN production and exposure,
which accelerates the process of DC maturation and acquisition of
T cell priming competence. Type-I IFN also up-regulates many
nucleic acid modifying and degrading enzymes that globally func-
tion to counteract viral replication in infected cells (18, 35), with
the consequences of promoting cytosolic nucleic acid degradation
and also potentially tRNA and rRNA decay. In activated DCs,
this processing could be detrimental to maintain robust pro-
tein synthesis and could interfere globally with the activation
process. Thus, enhanced Pol III activity in type-I IFN-exposed
DCs is required to adapt the translation machinery and allow
neosynthesis of molecules required for naïve T cell priming. Re-
placement of the tRNA pool could also have qualitative consequences
on the efficiency of translation of specific mRNAs and introduce
an additional layer of complexity to the gene expression regu-
latory program governing DC activation (36). The CK2/MAF1/
Pol III signaling axis represents a further pathway that could be
pharmacologically harnessed to control immunity and inflam-
mation in pathological situations.
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Supplemental Material and Methods 
Reagents 
Reagents and used concentrations were as follows: HMW Poly(I:C) (10 µg/mL)) was from InvivoGen; LPS 
(Escherichia coli O55:B5) (100 ng/ml), Rapamycin (100 nM) and Sodium Arsenite (500 µM, 30min) were 
from Sigma-Aldrich. RNA Polymerase III Inhibitor ML-60218 (50µM) was from Merck. CX-4945 
(Silmitasertib)(10 µM) was from Abcam. ISRIB (750 nM) was a gift from Peter Walter, UCSF, San 
Francisco.  
 
Mice 
Wild-type (WT) female C57BL/6 mice were purchased from Janvier, France; Ifnar1-/- mice (B6.129S2-
Ifnar1tm1agt) were a kind gift of Elena Tomasello (Dalod Lab, CIML); animals were maintained in the animal 
facility of Centre d’Immunologie de Marseille-Luminy (CIML). OT-II mice (12) on a RAG-2 deficient 
background were kept in CIPHE and were a kind gift of Sandrine Henri (Malissen Lab, CIML). Animals 
were kept under specific pathogen–free conditions accredited by the French Ministry of Agriculture to 
perform experiments on live mice. This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the French Ministry of 
Agriculture and of the European Union. All experiments were approved by the Comité d’éthique de 
Marseille and the Direction Départementale des Services Vétérinaires des Bouches du Rhône (approval 
number A13-543). All efforts were made to minimize animal suffering. 
 
Molecular Biology and gene expression analysis 
4 × 106 BM-DCs were transfected with 4 ug of origene pCMV6 mouse Maf1 plasmid and pCMV6 empty 
plasmid using the Amaxa Mouse Dendritic Cell Nucleofector™ Kit following the provider´s instructions. 
Cells were activated 12 h post transfection and analysed. FlexiTube siRNA targeting Maf1 and FlexiTube 
siRNA scramble as control (QIAGEN) were used for RNA silencing experiments. 4 × 106 BM-DCs were 
transfected with 1 µg of siRNA using the Amaxa Mouse Dendritic Cell Nucleofector™ Kit. Cells were 
activated 16 h post transfection and analysed. Total RNA was isolated using Trizol® (Invitrogen) and the 
Direct-zol™ kit (Zymo Research). cDNA was prepared with random hexamers and SuperScript III reverse 
transcriptase (Invitrogen). Real-time qPCR analysis was performed using SYBR Green PCR master mix 
(Takara) with Applied Biosystems PRISM 7700 Sequence Detection System. Primers are listed in Table 
S1. 
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Translation intensity measurement - Puromycin labelling 
Puromycin labelling for measuring translation levels was done as previously described (Schmidt et al., 
2009). Puromycin (Sigma-Aldrich) was added at 12,5μg/ml to the culture medium and the cells were 
incubated for 15 min at 37°C and 5% CO2. After puromycin incorporation the cells were harvested, washed 
in PBS and processed with Cytofix/Cytoperm buffer (BD Biosciences), stained with the anti-puromycin 
antibody (12D10) directly coupled with Alexa Fluor 488, and diluted in Perm/Wash buffer (BD Biosciences). 
Samples were acquired on a FACS Canto II (BD Biosciences), and data were analysed using FlowJo 
(Tree Star). 
 
Immunofluorescence 
Cells were harvested and dropped on a 12-mm coverslip covered with alcian blue. The coverslips were 
then incubated for 10 min at 37°C and fixed with 3,7% paraformaldehyde for 10min at room temperature. 
Cells were permeabilized with 0,1% Triton X-100 in 5% FCS PBS with 100 mM glycine, for 15 min at room 
temperature and stained over night at 4ºC with indicated primary antibodies, MAF1 (Abgent), G3BP1 and 
DCP1A (Santa Cruz). Coverslips were mounted using Prolong Gold and images taken with a laser-
scanning confocal microscope (LSM 780; Carl Zeiss MicroImaging) using a 63× objective and 
accompanying imaging software. Nuclear and cytosolic quantification was performed using the 
isolateCells.ijm Image J pluggin developed by Jan Valečka (CIML and Labex INFORM). 
 
Confocal immunofluorescence microscopy combined with fluorescent mRNA in situ hybridization 
(FISH) or immuno-proximity ligation assay. 
Cells on coverslips were fixed with 3.7% formaldehyde for 15 min, then permeabilized in 70% EtOH 
overnight and blocked with 5% bovine serum albumin (Sigma) containing ribonucleoside vanadyl complex 
(2 mM). Cells were stained for G3BP1 and RNase inhibitor (Rnasin, Promega) was added to the staining 
buffer. After this, cells were washed with 10% formamide in 2× SSC. A fluorescent probe (Quasar 570) 
against CD86 mRNA (Stellaris, Biosearch Technologies) was diluted in hybridization buffer containing 
dextran sulfate 10 mg/ml and 10% formamide in 2× SSC, according to the manufacturer's instructions. 
Probe was incubated with cells for 4 h at 37°C. Coverslips were mounted with Prolong Gold containing 
DAPI (Invitrogen). For immuno-proximity ligation assay (iPLA), cells were layered on a 12-mm coverslip 
covered with alcian blue. The coverslips were incubated for 10 min at 37°C and fixed with 3,7% 
paraformaldehyde for 10min at room temperature. iPLAs were done using the Duolink Kit according to the 
manufacturer’s instructions (Sigma-Aldrich). Specifically, the primary antibodies were: mTOR and CK2a 
from Santa Cruz and BRF1 was form Abcam. Duolink iPLA Probe anti-rabbit minus and anti-mouse plus 
were used.  Samples were incubated in the ligation solution consisting of Duolink Ligation Stock and 
Duolink Ligase. Detection of the amplified probe was done with the Duolink Detection Kit Orange.  All 
confocal microscopy images acquisition was performed with an LSM 780 laser-scanning microscope (Carl 
Zeiss MicroImaging) using a 63× objective. 
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Microarrays analysis. 
tRNA microarrays were performed as previously described (14). Shortly, total RNA (5-10 µg) was extracted 
from cells at basic conditions using TRIzol® (Invitrogen) which leads to complete deacylation of tRNAs 
(14). Cy3- or Atto647-labeled stem-loop RNA/DNA oligonucleotide was ligated overnight at 16°C with T4 
DNA ligase (NEB) to all deacetylated tRNAs. The tRNAs isolated from sample at the onset of experiment 
(zero-time point) were labeled with Atto647-labeled stem-loop oligonucleotide, while the samples 
representing other time points with Cy3-labeled one and hybridized together on one microarray for 16 h at 
60°C in.  The arrays were normalized to spike-in standards (14) and quantified with in-house python and 
R scripts. 
 
For gene expression analysis the total RNA was isolated with RNeasy kit (Qiagen). cDNA was synthesized 
with random hexamers and superscript II reverse transcriptase (Invitrogen). Quantitative real-time PCR 
analysis was performed with Applied Biosystems PRISM 7700 Sequence Detection System. The list of  
primers used is included in supplementary table 1. For Affymetrix microarray analysis, GM-CSF DCs were 
cultured in RPMI supplemented with 5 % FCS, 50µM beta-mercaptoethanol and GM-CSF. Cells 
differentiated for 6 days were treated for 8h with microbial stimuli and harvested before lysis. Control and 
Proteus mirabilis treated DCs were incubated with the bacteriostatic chloramphenicol to avoid bacterial 
growth. Guanabenz was used at 50 µM. Hybridization to arrays (Affymetrix GeneChip Mouse Gene 1.0ST) 
and image scanning were performed according to the Affymetrix Expression Analysis Technical Manual. 
Gene Expression microarray raw data were normalized using limmaGUI software (R/Bioconductor, 
Boston, MA, USA). Data are deposited in the GEO repository (GSE90831). 
 
 
T cell proliferation 
T cell proliferation assays were performed as described in (16). Briefly, the spleens and lymph nodes of 
OT-II Rag-2−/− mice were used, cells were isolated using a CD4 untouched Dynabeads® kit (Invitrogen).  
Purified OT-II Rag-2−/− T cells were labelled with CellTrace ™ Violet (Invitrogen). A total of 3 × 103 DCs 
were cocultured with 2 × 104 CTV-labeled OT-II Rag-2−/− T cells in 150 μL in the presence of ovalbumin 
(323-339) peptide (0.03 μg/mL). After 4 days of culture, proliferation (a loss of CTV staining) and Foxp3 
expression were measured by flow cytometry. Foxp3 expression levels were analysed using the Foxp3 
staining set (eBioscience) following the manufacturer's protocol. 
 
Statistical analysis  
Statistical analysis was performed using GraphPad Prism Software. * P<0.5, ** P<0.01, *** P< 0.001, 
****P<0.0001. Mainly unpaired Student’s t-test was used. Additionally, multiple comparisons analysis with 
the Holm-Sidak correction was used when comparing multiple treatments and covariance analysis was 
performed on the tRNA microarray data. 




Supplementary Table 1 
Primer sequences used for RT-qPCR. 
Target Sequence 
POLR3CFw  GGTAAGAGGAGGAGATCATCTG 
POLR3CRev  GGTTGACTTGCCAATAAATCCC 
Maf1Fw TTGCCAAGCCAACCCCACACT 
Maf1Rev TGCTTGCTCATCGAGGGAGGT 
IL6Fw AGTCCTTCCTACCCCAATTTCC 
IL6Rev GTCTTGGTCTGCTGCCACTCC 
TnfαFw GATATTGTTGCGAGGGCTGCC 
TnfαRev GAGGATTGCTATCACACTATTC 
Internal control CAATTGCAGATGAGATGGATCA 
RPS16Fw   ATTTGCTGGTGTGGATATTCG 
RPS16Rev   CTTGGAGGCTTCATCCACATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2 
tRNAs expression levels in WT and IFNAR -/- DCs stimulated with LPS for 8h. tRNAs were quantified by tRNA-
tailored microarrays. tRNAs are represented by the anticodon and cognate amino acid. Meti-CAU denotes 
initiator tRNA pairing to AUG start codon. Data are means of two biological replicates which were highly 
reproducible similar 0.76, 0.85, 0.88 and 0.87 (Kolmogorov-Smirnov test) for WT LPS 4h, WT LPS 8h, IFNAR-
/- LPS 4h and IFNAR-/- 8h, respectively. Bold indicates a considerably higher expression of the tRNA in IFNAR-
/- DC stimulated for 8h with LPS than in WT cells. 
tRNA WT LPS 4h WT LPS 8h IFNAR-/- LPS 4h  IFNAR-/- LPS 8h 
Arg-ICG 1,61 0,83 0,72 1,65 
Arg-C/UCG 1,56 0,80 0,67 1,61 
Arg-CCU 1,55 0,95 0,99 2,01 
Arg-UCU 1,67 0,88 0,83 1,50 
His-GUG 1,40 1,06 1,19 0,96 
Lys-CUU 1,38 0,93 0,81 0,79 
Lys-UUU1 1,44 0,87 0,92 3,38 
Lys-UUU2 1,33 1,04 0,81 0,73 
Lys-UUU3 1,57 0,95 1,15 1,42 
Asp-GUC 1,13 0,75 0,59 0,70 
Glu-UUC 1,30 0,79 0,78 1,25 
Glu-C/UUC 1,22 0,79 0,83 1,12 
Asn-GUU 1,40 0,83 0,80 1,07 
Cys-UGU/C 1,35 0,98 0,94 1,50 
Gln-C/UUU 1,30 1,01 0,99 2,01 
Ser-CGA 1,23 1,04 0,89 0,89 
Ser-A/G/UGA 1,30 1,06 0,80 0,69 
Ser-GCU 1,15 0,97 0,82 0,72 
Thr-A/CGU 1,37 1,16 1,04 1,15 
Thr-UGU 1,46 1,05 0,99 1,44 
Thr-CGU 1,91 1,47 0,91 1,32 
Ala-A/C/UGC 1,31 1,10 0,98 2,76 
Gly-G/CCC 1,54 1,17 0,58 1,57 
Gly-UCC 1,06 1,09 1,10 1,35 
Ile-IAU 1,32 1,35 0,92 1,70 
Ile-UAU 2,13 1,07 0,94 3,34 
Leu-A/UAG 1,54 1,05 0,92 2,31 
Leu-CAG 1,45 0,94 0,89 2,14 
Leu-CAA 1,43 1,06 0,99 1,43 
Leu-UAA1 1,76 0,95 0,78 1,88 
Leu-UAA2 1,26 0,76 0,94 3,52 
Meti-CAU 1,02 0,90 1,13 1,18 
Met-CAU 1,32 1,11 0,95 1,59 
Phe-GAA 1,25 1,18 0,99 1,35 
Pro-A/C/UGG 1,39 0,85 0,71 0,66 
Sec-UCA2 1,18 1,04 0,85 0,64 
Trp-CCA 1,33 1,02 0,99 1,39 
Tyr-GUA 1,13 0,89 0,78 0,71 
Val-mAC 1,08 1,06 0,92 0,89 
Val-UAC 1,50 1,24 0,97 1,04 
Supplementary Table 3 
Covariance analysis of the tRNAs expression levels in DCs stimulated with LPS for 4 
and 8h. The values for WT (A) and IFNAR -/-  (B) DCs stimulated for 4 and 8h were 
compared. tRNAs are represented by the anticodon and cognate amino acid. Meti-CAU 
denotes initiator tRNA pairing to AUG start codon. 
 
 
 
